New drug combo trial targets breast cancer in the brain
NCT ID NCT07152782
Summary
This study is testing whether adding a drug called neratinib to a standard treatment (Trastuzumab Deruxtecan) works better for controlling advanced HER2-positive breast cancer that has spread to the brain. It will involve 202 women in China who will receive one of the two treatment plans. The main goal is to see which approach keeps the cancer from getting worse for a longer time, with a focus on controlling the cancer in the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.